Sarepta Therapeutics, Inc.
$2.27B- Market cap
- $2.38B
- Debt
- +$828.97M
- Cash
- −$939.65M
Capital structure 74% equity / 26% debt · EV / Revenue 1.03x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: SRPT stock price at discount vs OGE $22.50 current versus $61.81 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OGE's multiple
Implied fair value · at SRPT's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · OGE FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 74% equity / 26% debt · EV / Revenue 1.03x
Capital structure 63% equity / 37% debt · EV / Revenue 4.71x · EV / EBITDA 9.95x
OGE carries the larger enterprise value at $15.34B against $2.27B; SRPT trades on the lower EV / Revenue multiple (1.03x vs 4.71x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SAREPTA THERAPEUTICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
OGE ENERGY CORP. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.73x
1.14x
Net debt / EBITDA
Leverage against operating earnings
0.17x
3.67x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$200.00K
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
CENTERPOINT ENERGY INC
SRPT vs CNP
ALLIANT ENERGY CORP
SRPT vs LNT
AMERICAN ELECTRIC POWER CO INC
SRPT vs AEP
XCEL ENERGY INC
SRPT vs XEL
Evergy, Inc.
SRPT vs EVRG
PINNACLE WEST CAPITAL CORP
SRPT vs PNW
$828.97M
$5.66B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SRPT can materially improve margins and sustain growth without further deterioration in quality scores, then the stock could merit upside from a P/S rerating; otherwise, the data favors caution because the low multiple is paired with negative profitability, weak ROIC, and distress-like quality signals.
SRPT trades at 0.9x P/S versus OGE at 3.1x, and the provided P/S-based model implies a price of $65.53 versus the current $19.28, or 239.9% upside. However, that gap is driven by a revenue-multiple comparison that ignores SRPT's negative margins and losses, while the historical band of $17.35 to $21.21 shows the stock is already trading near its recent range.
Supporting Metrics